Extended-release nicotinic acid with

Sampathkumar et al. 2006 Single treatment of 34 extended release nicotinic acid (375 mg) tablet in patients on haemodialysis for a mean period of eight months. This was associated with a significant decrease in both plasma phosphate and calcium phosphate product. Restrepo et al. 2008 In nine patients with CKD and on dialysis treated with 1000 mg nictonic acid for eight months decreased LDL-c, triglyceride and increased HDL-c. The authors recommended that nicotinic acid is efficient, very well tolerated and economical in comparison with other drugs, which makes it ideal for the treatment of patients with hyperlipidaemia and refractory hyperphosphatemia to classical treatments. 

Vega, G.L., Cater, N.B., Meguro, S., and Grundy, S.M., 2005. Influence of extended release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. American Journal of Cardiology. 95 1309 1313. 

Dosing of nicotinic acid should be titrated to minimize adverse effects. An initial dose of 50 to 100 mg t.i.d. often is used with immediate-release tablets. The dose then is gradually increased by 50 to 100 mg every 3 to 14 days, up to a maximum of 6 g/day, as tolerated. Therapeutic monitoring to assess efficacy and prevent toxicity is essential until a stable and effective dose is reached. Similar dosing escalations are available for extended-release products, with doses normally starting at 500 mg once daily at bedtime. (7,15,21). 

---